Contract development and manufacturing organization (CDMO) WuXi Biologics has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, BioVaxys Technology’s COVID-19 vaccine candidate, and CoviDTH, its immunodiagnostic product. Both are headed for clinical trials, with BioVaxys having begun preparing an IND submission to the U.S. FDA for a combined Phase I/II clinical study of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.   Under the terms of the a...